A New KIT Mutation (N505I) in Acral Melanoma Confers Constitutive Signaling, Favors Tumorigenic Properties, and Is Sensitive to Imatinib - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Journal of Investigative Dermatology Année : 2014

A New KIT Mutation (N505I) in Acral Melanoma Confers Constitutive Signaling, Favors Tumorigenic Properties, and Is Sensitive to Imatinib

Résumé

no abstract

Domaines

Cancer

Dates et versions

inserm-02530592 , version 1 (03-04-2020)

Identifiants

Citer

Maryline Allegra, Damien Giacchero, Coralie Segalen, Nicolas Dumaz, Catherine Butori, et al.. A New KIT Mutation (N505I) in Acral Melanoma Confers Constitutive Signaling, Favors Tumorigenic Properties, and Is Sensitive to Imatinib. Journal of Investigative Dermatology, 2014, 134 (5), pp.1473-1476. ⟨10.1038/jid.2013.525⟩. ⟨inserm-02530592⟩
33 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More